Proton Therapy for Unresectable Cancer (CA) of Pancreas (PC01)
Pancreatic Cancer
About this trial
This is an interventional treatment trial for Pancreatic Cancer focused on measuring Pancreatic cancer, Unresectable, Proton radiation, Chemotherapy
Eligibility Criteria
Inclusion Criteria:
Pathologically confirmed adenocarcinoma of the pancreas.
Patients must be medically inoperable or have unresectable disease
Exclusion Criteria:
- Evidence of distant metastasis; evidence of metastatic disease in the major viscera (organs), peritoneal seeding and/or ascites.
- Previous irradiation to the abdomen that would compromise the ability to deliver the prescribed treatment.
- Prior surgical resection.
Sites / Locations
- University of Florida Proton Therapy Institute
Arms of the Study
Arm 1
Experimental
Proton radiation and chemotherapy
Chemotherapy and Radiation Combination Proton radiation 59.4 cobalt gray equivalent(CGE) in 33 fx at 1.8 CGE per fx over 7 weeks. Capecitabine (Xeloda ®) 1,000 mg by mouth approximately every 12 hrs, 5 days/week starting the first day of radiation until the end of radiation, but on radiation days only. Consolidation Chemotherapy starting 4 weeks after the completion of radiation Gemcitabine (Gemzar ®) Suggested Regimen - 1,000mg/m2 by IV over 30 minutes once a week for 3 weeks (followed by a week of rest) for 12 total doses.